|
 |
| home > epc > autumn 2004 > searching broader horizons - opportunities for clinical trials in india |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
There are frequent announcements in the industry press of companies, in particular multinational CROs, expanding their geographical areas for the purpose of conducting clinical trials by establishing offices and commencing operations in countries that emerged as sources of clinical trial data in the 1990s, for example Central and Eastern Europe (CEE). This influx has led some CROs that were initially set up to conduct trials in these countries to locate, explore and establish operations further afield in order to discover large pools of treatment-naïve patients.
Many articles are routinely seen in journals extolling the virtues of contract research in Central and Eastern Europe. Countries like Poland are becoming saturated with clinical trials operating at Western European levels. Costs in Poland are being driven up, and salaries and benefits for experienced staff (who are hard to find in a competitive market, despite an overall unemployment rate in the country of 20 per cent) are fast-approaching the rates paid in Western European operations. The accession to the EU of Poland, the Czech Republic, Hungary, Slovakia, Slovenia, Estonia, Latvia and Lithuania, and the freedom of movement between EU member countries, has encouraged and permitted greater freedom and potential career enhancement for clinical staff qualified and trained in the CEE.
Companies with a strong presence and many years' experience in conducting clinical trials in this region are now looking to other areas of the globe for their continued expansion, widening the search for large pools of treatment-naive patients, motivated and well-qualified investigators and a wide range of conditions.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
